Chronic heart failure
351 results
101 - 200
Dyspnoea 
Glucagon‐like peptide 1 (GLP‐1) receptor agonists for people with chronic kidney disease and diabetes
Dapagliflozin reduces mortality and hospitalization rates for patients with mild heart failure and reduced ejection fraction- Interpreting BNP in patients with a history of HF
- SGLT2 inhibitors ("-flozin" meds) improve all-cause and CV mortality in patients regardless of diabetes or HF status
- BNP-guided tx decreases CHF mortality
- Leg oedema
- Sotagliflozin reduces hospitalizations and urgent visits for heart failure, but has no mortality benefit (SCORED)
- Minimal, if any, cardiovascular benefit from intravenous iron for adults with heart failure and iron deficiency
- Aldosterone receptor antagonists spironolactone and eplerenone for congestive heart failure
- Long-term adverse effects of antineoplastic agents
- Hyperkalaemia
- Rhythm control improves quality of life in patients with CHF and AF
- Safe use of non-steroidal anti-inflammatory drugs (NSAIDs)
- Hyperglycaemic hyperosmolar syndrome
- Antiplatelet versus anticoagulation treatment for people with heart failure in sinus rhythm
- Drug treatment for hypertension
- Remote digital monitoring for selected chronic diseases in primary health care
- Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure
- No benefit with torsemide over furosemide for posthospitalization treatment of heart failure (TRANSFORM-HF)
- Darbepoetin alfa does not improve HF outcomes
- Pneumonia
- Respiratory failure
- Acute cardiovascular events are common in patients hospitalized with influenza
- Rosuvastatin has no effect on clinical outcomes in CHF
- Cardioselective beta‐blockers for chronic obstructive pulmonary disease
- Beta-blockers don't decrease mortality in patients with AF + CHF
- Non‐invasive positive pressure ventilation for central sleep apnoea in adults
- Mitral regurgitation
- Increased pulmonary blood pressure: pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
- Antiplatelet agents for chronic kidney disease
- Organ transplant recipient in primary health care
- Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease
- Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
- Hypertension in elderly patients
- Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease
- Structured telephone support or non‐invasive telemonitoring for patients with heart failure
- Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease
- Amyloidosis
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
- SGLT2 inhibitors, GLP1 agonists provide greater benefit for patients with type 2 diabetes
- SGLT-2 inhibitors and GLP-1 agonists for diabetes and chronic kidney disease
- In high-risk older patients with atrial fibrillation, rhythm control reduces cardiovascular death and stroke, but at a price
- Post-MI beta-blockers do not decrease mortality
- Aldosterone antagonists for people with chronic kidney disease requiring dialysis
- A patient with jaundice (icterus)
- Sodium‐glucose co‐transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
- Chronic diseases and pregnancy
- Dietary interventions for adults with chronic kidney disease
- Haemochromatosis
- Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews
- Assessing a patient with an abnormal liver function test result
- Drugs for ventricular rate control in atrial fibrillation
- Oxygen therapy for dyspnoea in adults: Cochrane systematic review
- Acute kidney injury
- Systemic sclerosis
- Dronedarone in atrial fibrillation
- Cardioselective beta‐blockers for reversible airway disease
- Taking furosemide on day of surgery does not increase intraop hypotension
- Angiotensin receptor blockers for heart failure
- Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD)
- Continuous infusion versus bolus injection of loop diuretics for acute heart failure
- Bolus loop diuretics = continuous infusion in treatment of CHF (DOSE trial)
- Greater continuity of care associated with fewer preventable hospitalizations
- Excessive sweating (hyperhidrosis)
- Endovascular versus open surgical repair for complicated chronic Type B aortic dissection
- COVID-19 research briefs: case series of critically ill patients in the intensive care unit
- 2022 NICE guidance: type 2 diabetes
- Erythropoiesis‐stimulating agents for anaemia in adults with chronic kidney disease: a network meta‐analysis
- CV interventions in old elderly are not useful (DEBATE)
- Decreased hospital LOS not associated with increase in 30-day readmission rates
- Hyponatraemia
- Deep vein thrombosis
- Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease
- Treatment of acute hypoxemic respiratory failure with noninvasive ventilation using a helmet or face mask led to fewer deaths
- Chronic coronary syndrome (coronary heart disease)
- Anticoagulation versus placebo for heart failure in sinus rhythm
- CRP concentration in the diagnostics of lower respiratory infections
- Dapagliflozin reduces mortality and renal replacement in patients with chronic kidney disease
- Hydralazine in infants with persistent hypoxemic respiratory failure: Cochrane systematic review
- mHealth education interventions in heart failure